Why Novartis is sitting pretty

Posted 6 December 2023 AM

After a tumultuous couple of years including a major workforce downsize, a pipeline cull and spinning-off its generics and biosimilars business - things are looking up for Novartis.

The company is drilling down on its 'pure play' strategy with a laser-focus on four therapeutic areas  and it appears to be paying off.

To see the whole article, please login